Factors identified for increased post-surgery weight gain among breast cancer survivors
the ONA take:
According to a new study published in the journal BMC Cancer, researchers have found that average long-term weight gain among breast cancer survivors is small, but certain subgroups of women experience greater weight gain associated with adverse health.
For the study, researchers sought to investigate body weight changes following breast cancer over 6 years and whether weight changes are linked with behavioral, diagnostic, personal, or treatment characteristics. Researchers identified 287 Australian women diagnosed with early-stage invasive breast cancer.
Results showed that 57% of women were overweight or obese at 6 months post-surgery, which increased to 68% at 72 months post-surgery. Researchers found that 24% of participants experienced clinically significant weight gain between 6 and 18 months and 39% experienced clinically significant weight gain between 6 and 72 months post-surgery.
In addition, researchers found that more extensive lymph node removal, receiving radiation therapy, being treated on the non-dominant side, and decreased physical activity levels at 6 months post-surgery were associated with higher body weights after breast cancer.
The findings suggest that healthy weight education should be integrated into breast cancer care to improve the quality of cancer survivorship.
Average long-term weight gain among breast cancer survivors is small, but certain subgroups experience greater gain associated with adverse health.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|